Article
作者: Wang, Yu ; Li, Shanshan ; Li, Yuzhen ; Jia, Huifeng ; Zhan, Yifan ; Jiang, Congjun ; Situ, Xiaolu ; Wu, Liming ; Ma, Chi ; Tu, Ying ; Yang, Baoqi ; Zhu, Xiangyang ; Ji, Mingkai ; Qian, Qiaoxia ; Zhang, Furen ; Zhou, Guodong ; Ma, Xiuqiang ; Cui, Xiaopei ; Xu, Bo ; Yang, Liuyi ; Wang, Xiaohua ; Zhou, Cheng ; Ji, Chao ; Man, Xiaoyong ; Li, Linfeng ; Feng, Yanyan ; Ding, Yangfeng ; Zhang, Jianzhong ; Lei, Tiechi ; Xiang, Niu ; Chen, Qian ; Shen, Zhu ; Li, Benke ; Zhang, Zhenying ; Wang, Jianbo
Background:Generalized pustular psoriasis (GPP) is a rare, severe inflammatory skin disease characterized by acute flares. Recibokibart is a humanized IgG1 monoclonal antibody targeting the interleukin (IL)-36 receptor. In a phase Ib open-label study, a single intravenous dose of recibokibart was associated with an acceptable safety profile and rapid improvements in pustulation, overall skin disease severity and systemic inflammatory markers through 12 weeks.
Objectives:To evaluate the efficacy and safety of recibokibart in patients with acute flares of GPP.
Methods:In this multicentre, randomized, double-blind, placebo-controlled phase II trial conducted in China, patients with moderate-to-severe acute GPP were randomly assigned in a 2 : 1 ratio to receive a single intravenous dose of recibokibart (1050 mg) or placebo at day 1. Patients with persistent disease activity at day 8 were eligible to receive open-label recibokibart, and patients with recurrent flares after achieving a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of 0 or 1 could receive an additional open-label dose. The primary efficacy endpoint was the proportion of patients who achieved a GPPGA pustulation subscore of 0 or 1 at week 1 (day 8).
Results:A total of 33 patients were randomized (recibokibart, n = 22; placebo, n = 11). At week 1 (day 8), the primary endpoint of achieving a GPPGA pustulation subscore of 0 or 1 was met by 86% of patients in the recibokibart group vs. 9% in the placebo group (between-group difference 77.3%, 95% confidence interval 42.5–88.9; P < 0. 001). At week 1 (day 8), greater improvements were observed with recibokibart vs. placebo across key secondary endpoints, including achievement of a GPPGA total score of 0 or 1 (64% vs. 0%), complete pustule clearance (55% vs. 0%), and mean percentage change from baseline in GPPASI (−59.3% vs. 0%). By week 4, 73% of patients treated with recibokibart achieved ≥ 75% improvement from baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI). Clinical improvements were observed as early as 24 h after treatment and were maintained through week 12, although assessments after day 8 included patients who received open-label treatment. The most frequently reported adverse events with recibokibart included hypoproteinaemia, hypertriglyceridaemia, hyperlipidaemia and pruritus.
Conclusions:A single intravenous dose of recibokibart resulted in rapid improvement in pustular and overall skin disease severity in patients with acute GPP flares, with an acceptable safety profile.